Pauline Williams is Head of Global Health R&D at GSK. She leads a team of physicians and scientists discovering and developing new medicines for diseases predominantly affecting patients in the developing world, including TB and Malaria.
In partnership with Save the Children, Dr Williams initiated and led the development of Umbipro™ for prevention of neonatal sepsis, now approved in 12 countries with high neonatal mortality.
Her team is responsible for tafenoquine, recently approved by the FDA for the radical cure (prevention of relapse) of malaria vivax. Her team also supports open innovation global health research, including the GSK Non-communicable Diseases Open Lab and the Tres Cantos Open Lab.
A physician by training, Dr Williams has spent most of her career in industry, focusing on clinical development in partnership with academia. She is a Fellow of the Academy of Medical Sciences and a Council Member of the Medical Research Council.